Vestal Point Capital, LP
Filing Date
Global Rank
#834
/ 8,623
▲ 124
· as of Mar 2026
Top Industry
Biotechnology
75.4%
3Y Alpha vs SPY
+14.4%
Period ended 4 months ago
Filed May 15, 2026 · 3mo
10 quarters · since Dec 2023
Clone Performance
Feb 2024–Jul 2026 · vs SPYHypothetical growth of buying every stock this filer reported holding, rebalancing on each filing and indexed to the same start. Option positions cannot be bought this way and are left out.
Cloned portfolio
+99.1%
SPY
+50.3%
Annualised alpha
+14.3%
Max drawdown
−31.4%
Estimate. 13F holdings are quarter-lagged, so the clone rebalances about 45 days after each period end — when the filing becomes public — and it excludes option and short positions. It tracks 99% of reported value on average across 10 quarters. Past performance does not predict future results.
Portfolio Concentration
90 tracked positions · as of Mar 31, 2026 · Δ vs Dec 31, 2025Top Position
6.5%
−2.3 pts
Top 5
25.4%
−9.5 pts
Top 10
40.4%
−9.9 pts
HHI
255
Diversified−111
Portfolio Trend
10 quarters · across all stocks
Sector Breakdown
As of Mar 31, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 100.0% | $3,576,817,338 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased
25 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| BCRX | Biocryst Pharmaceuticals Inc | +4,775,000 | 7,025,000 | $66,878,000 | |
| TSHA | Taysha Gene Therapies, Inc. | +4,250,000 | 18,000,000 | $80,460,000 | |
| DYN | Dyne Therapeutics, Inc. | +3,880,000 | 4,000,000 | $72,520,000 | |
| GLUE | Monte Rosa Therapeutics, Inc. | +2,828,465 | 3,603,465 | $59,276,999 | |
| IMCR | Immunocore Holdings plc | +2,181,868 | 2,766,868 | $83,421,070 | |
| RVMD | Revolution Medicines, Inc. | +2,080,000 | 2,375,000 | $230,968,750 | |
| BCAX | Bicara Therapeutics Inc. | +1,850,000 | 5,425,000 | $107,903,250 | |
| NRIX | Nurix Therapeutics, Inc. | +1,810,000 | 6,500,000 | $100,750,000 | |
| BBNX | Beta Bionics, Inc. | +1,611,518 | 2,211,518 | $22,159,410 | |
| VYGR | Voyager Therapeutics, Inc. | +1,527,936 | 3,002,936 | $11,591,332 | |
| ARWR | Arrowhead Pharmaceuticals, Inc. | +1,375,000 | 2,275,000 | $142,642,500 | |
| DNLI | Denali Therapeutics Inc. | +1,308,326 | 1,773,326 | $34,047,859 | |
| OKUR | OnKure Therapeutics, Inc. | +1,204,819 | 1,839,819 | $7,616,850 | |
| ENGN | enGene Therapeutics Inc. | +1,110,000 | 2,165,000 | $14,743,650 | |
| SVRA | Savara Inc | +994,052 | 2,600,052 | $14,196,283 | |
| RGEN | Repligen Corp | +842,000 | 925,000 | $108,983,500 | |
| VERA | Vera Therapeutics, Inc. | +818,159 | 1,368,159 | $55,041,036 | |
| BMY | Bristol Myers Squibb Co | +750,000 | 1,000,000 | $60,650,000 | |
| SRRK | Scholar Rock Holding Corp | +624,422 | 1,324,422 | $65,108,585 | |
| BMRN | Biomarin Pharmaceutical Inc | +575,000 | 3,575,000 | $201,951,750 | |
| APGE | Apogee Therapeutics, Inc. | +550,000 | 1,100,000 | $92,587,000 | |
| NUVL | Nuvalent, Inc. | +435,715 | 481,715 | $49,351,701 | |
| MYGN | Myriad Genetics Inc | +425,000 | 1,648,000 | $7,416,000 | |
| RAPP | Rapport Therapeutics, Inc. | +326,229 | 1,436,229 | $44,939,605 | |
| ASND | Ascendis Pharma A/S | +200,000 | 375,000 | $85,773,750 | |
| No positions match the current search. | |||||
Trimmed
Positions the filer reduced
14 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| GERN | Geron Corp | −8,780,000 | 2,540,000 | $3,784,600 | |
| TERN | Terns Pharmaceuticals, Inc. | −3,500,000 | 1,000,000 | $52,720,000 | |
| TYRA | Tyra Biosciences, Inc. | −2,371,000 | 54,000 | $2,068,200 | |
| OLMA | Olema Pharmaceuticals, Inc. | −1,221,449 | 428,551 | $6,389,695 | |
| SLDB | Solid Biosciences Inc. | −815,000 | 5,000,000 | $36,000,000 | |
| GMED | Globus Medical Inc | −664,480 | 610,520 | $52,602,403 | |
| ELVN | Enliven Therapeutics, Inc. | −580,000 | 3,250,000 | $127,400,000 | |
| ANRO | Alto Neuroscience, Inc. | −420,925 | 2,064,075 | $46,400,406 | |
| ABVX | Abivax S.A. | −400,000 | 1,500,000 | $167,025,000 | |
| ALC | Alcon Inc | −305,000 | 800,000 | $60,280,000 | |
| NVCR | NovoCure Ltd | −275,000 | 250,000 | $2,725,000 | |
| NYXH | Nyxoah SA | −238,339 | 868,661 | $2,536,490 | |
| KALV | KalVista Pharmaceuticals, Inc. | −40,000 | 1,850,000 | $37,240,500 | |
| IRON | Disc Medicine, Inc. | −35,000 | 700,000 | $44,758,000 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarter
25 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| NBIX | Neurocrine Biosciences Inc | 1,250,000 | $164,675,000 | |
| SNY | Sanofi | 1,400,000 | $67,452,000 | |
| BSX | Boston Scientific Corp | 800,000 | $50,200,000 | |
| COGT | Cogent Biosciences, Inc. | 1,230,888 | $47,376,879 | |
| UTHR | UNITED THERAPEUTICS Corp | 75,000 | $44,473,500 | |
| DRUG | Bright Minds Biosciences Inc. | 492,319 | $35,924,517 | |
| PTGX | Protagonist Therapeutics, Inc | 326,159 | $34,377,158 | |
| REGN | Regeneron Pharmaceuticals, Inc. | 40,000 | $30,905,600 | |
| WAT | Waters Corp /De/ | 100,000 | $29,780,000 | |
| VKTX | Viking Therapeutics, Inc. | 914,147 | $29,746,343 | |
| INSP | Inspire Medical Systems, Inc. | 539,269 | $27,815,495 | |
| TRVI | Trevi Therapeutics, Inc. | 2,166,504 | $25,846,392 | |
| SLNO | Soleno Therapeutics Inc | 730,000 | $24,440,400 | |
| NKTR | Nektar Therapeutics | 285,000 | $20,505,750 | |
| CYTK | Cytokinetics Inc | 300,000 | $19,773,000 | |
| AZN | Astrazeneca PLC | 100,000 | $19,722,000 | |
| WST | West Pharmaceutical Services Inc | 75,000 | $18,798,000 | |
| GEHC | GE HealthCare Technologies Inc. | 250,000 | $17,795,000 | |
| SGP | SpyGlass Pharma, Inc. | 666,760 | $17,275,751 | |
| MDGL | Madrigal Pharmaceuticals, Inc. | 31,468 | $16,472,553 | |
| WGS | GeneDx Holdings Corp. | 250,000 | $16,055,000 | |
| DMRA | Damora Therapeutics, Inc. | 600,000 | $15,540,000 | |
| TARS | Tarsus Pharmaceuticals, Inc. | 200,000 | $14,030,000 | |
| PODD | Insulet Corp | 50,601 | $10,618,113 | |
| SRZN | Surrozen, Inc./DE | 338,611 | $9,863,738 | |
| No positions match the current search. | ||||
Sold Out
Positions the filer fully exited
22 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| QQQ | Invesco Qqq Trust, Series 1 | 350,000 | $215,008,500 | |
| ACLX | Arcellx, Inc. | 2,925,000 | $190,710,000 | |
| DXCM | Dexcom Inc | 1,275,000 | $84,621,750 | |
| MRK | Merck & Co., Inc. | 775,000 | $81,576,500 | |
| ABT | Abbott Laboratories | 600,000 | $75,174,000 | |
| JAZZ | Jazz Pharmaceuticals plc | 290,000 | $49,300,000 | |
| DAWN | Day One Biopharmaceuticals, Inc. | 5,200,000 | $48,464,000 | |
| AXSM | Axsome Therapeutics, Inc. | 210,000 | $38,354,400 | |
| LNTH | Lantheus Holdings, Inc. | 360,000 | $23,958,000 | |
| ZYME | Zymeworks Inc. | 865,000 | $22,775,450 | |
| UPB | Upstream Bio, Inc. | 720,000 | $19,548,000 | |
| PEN | Penumbra Inc | 50,000 | $15,545,500 | |
| GILD | Gilead Sciences, Inc. | 50,000 | $6,137,000 | |
| DBVT | DBV Technologies S.A. | 300,000 | $5,751,000 | |
| MIRM | Mirum Pharmaceuticals, Inc. | 66,000 | $5,213,340 | |
| LENZ | LENZ Therapeutics, Inc. | 275,000 | $4,400,000 | |
| RZLT | Rezolute, Inc. | 1,686,000 | $3,978,960 | |
| STRO | Sutro Biopharma, Inc. | 243,000 | $2,811,510 | |
| GPCR | Structure Therapeutics Inc. | 35,000 | $2,434,250 | |
| BDTX | Black Diamond Therapeutics, Inc. | 870,000 | $2,114,100 | |
| FATE | Fate Therapeutics Inc | 1,725,000 | $1,690,500 | |
| ALEC | Alector, Inc. | 755,000 | $1,177,800 | |
| No positions match the current search. | ||||
90 tracked positions ·
$3,576,817,338 total
· filing declares
90 positions · $3,576,817,318
· as of Mar 31, 2026
Showing 1–50
of 90 positions by value
· page 1 of 2
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| RVMD |
Revolution Medicines, Inc.
Healthcare
|
Added | 2,375,000 | $230,968,750 | 6.46% | |
| BMRN |
Biomarin Pharmaceutical Inc
Healthcare
|
Added | 3,575,000 | $201,951,750 | 5.65% | |
| ABVX |
Abivax S.A.
Healthcare
|
Reduced | 1,500,000 | $167,025,000 | 4.67% | |
| NBIX |
Neurocrine Biosciences Inc
Healthcare
|
NEW | 1,250,000 | $164,675,000 | 4.60% | |
| ARWR |
Arrowhead Pharmaceuticals, Inc.
Healthcare
|
Added | 2,275,000 | $142,642,500 | 3.99% | |
| ELVN |
Enliven Therapeutics, Inc.
Healthcare
|
Reduced | 3,250,000 | $127,400,000 | 3.56% | |
| RGEN |
Repligen Corp
Healthcare
|
Added | 925,000 | $108,983,500 | 3.05% | |
| BCAX |
Bicara Therapeutics Inc.
Healthcare
|
Added | 5,425,000 | $107,903,250 | 3.02% | |
| NRIX |
Nurix Therapeutics, Inc.
Healthcare
|
Added | 6,500,000 | $100,750,000 | 2.82% | |
| APGE |
Apogee Therapeutics, Inc.
Healthcare
|
Added | 1,100,000 | $92,587,000 | 2.59% | |
| ASND |
Ascendis Pharma A/S
Healthcare
|
Added | 375,000 | $85,773,750 | 2.40% | |
| IMCR |
Immunocore Holdings plc
Healthcare
|
Added | 2,766,868 | $83,421,070 | 2.33% | |
| TSHA |
Taysha Gene Therapies, Inc.
Healthcare
|
Added | 18,000,000 | $80,460,000 | 2.25% | |
| DYN |
Dyne Therapeutics, Inc.
Healthcare
|
Added | 4,000,000 | $72,520,000 | 2.03% | |
| SNY |
Sanofi
Healthcare
|
NEW | 1,400,000 | $67,452,000 | 1.89% | |
| BCRX |
Biocryst Pharmaceuticals Inc
Healthcare
|
Added | 7,025,000 | $66,878,000 | 1.87% | |
| SRRK |
Scholar Rock Holding Corp
Healthcare
|
Added | 1,324,422 | $65,108,585 | 1.82% | |
| IMTX |
Immatics N.V.
Healthcare
|
Added | 6,175,000 | $60,762,000 | 1.70% | |
| BMY |
Bristol Myers Squibb Co
Healthcare
|
Added | 1,000,000 | $60,650,000 | 1.70% | |
| ALC |
Alcon Inc
Healthcare
|
Reduced | 800,000 | $60,280,000 | 1.69% | |
| GLUE |
Monte Rosa Therapeutics, Inc.
Healthcare
|
Added | 3,603,465 | $59,276,999 | 1.66% | |
| VERA |
Vera Therapeutics, Inc.
Healthcare
|
Added | 1,368,159 | $55,041,036 | 1.54% | |
| TERN |
Terns Pharmaceuticals, Inc.
Healthcare
|
Reduced | 1,000,000 | $52,720,000 | 1.47% | |
| GMED |
Globus Medical Inc
Healthcare
|
Reduced | 610,520 | $52,602,403 | 1.47% | |
| BSX |
Boston Scientific Corp
Healthcare
|
NEW | 800,000 | $50,200,000 | 1.40% | |
| NUVL |
Nuvalent, Inc.
Healthcare
|
Added | 481,715 | $49,351,701 | 1.38% | |
| COGT |
Cogent Biosciences, Inc.
Healthcare
|
NEW | 1,230,888 | $47,376,879 | 1.32% | |
| ANRO |
Alto Neuroscience, Inc.
Healthcare
|
Reduced | 2,064,075 | $46,400,406 | 1.30% | |
| RAPP |
Rapport Therapeutics, Inc.
Healthcare
|
Added | 1,436,229 | $44,939,605 | 1.26% | |
| IRON |
Disc Medicine, Inc.
Healthcare
|
Reduced | 700,000 | $44,758,000 | 1.25% | |
| UTHR |
UNITED THERAPEUTICS Corp
Healthcare
|
NEW | 75,000 | $44,473,500 | 1.24% | |
| CLDX |
Celldex Therapeutics, Inc.
Healthcare
|
Added | 1,224,165 | $38,830,513 | 1.09% | |
| KALV |
KalVista Pharmaceuticals, Inc.
Healthcare
|
Reduced | 1,850,000 | $37,240,500 | 1.04% | |
| XENE |
Xenon Pharmaceuticals Inc.
Healthcare
|
Added | 639,900 | $37,210,185 | 1.04% | |
| SLDB |
Solid Biosciences Inc.
Healthcare
|
Reduced | 5,000,000 | $36,000,000 | 1.01% | |
| DRUG |
Bright Minds Biosciences Inc.
Healthcare
|
NEW | 492,319 | $35,924,517 | 1.00% | |
| PTGX |
Protagonist Therapeutics, Inc
Healthcare
|
NEW | 326,159 | $34,377,158 | 0.96% | |
| DNLI |
Denali Therapeutics Inc.
Healthcare
|
Added | 1,773,326 | $34,047,859 | 0.95% | |
| REGN |
Regeneron Pharmaceuticals, Inc.
Healthcare
|
NEW | 40,000 | $30,905,600 | 0.86% | |
| WAT |
Waters Corp /De/
Healthcare
|
NEW | 100,000 | $29,780,000 | 0.83% | |
| VKTX |
Viking Therapeutics, Inc.
Healthcare
|
NEW | 914,147 | $29,746,343 | 0.83% | |
| INSP |
Inspire Medical Systems, Inc.
Healthcare
|
NEW | 539,269 | $27,815,495 | 0.78% | |
| CBIO |
Crescent Biopharma, Inc.
Healthcare
|
Held | 1,500,000 | $27,555,000 | 0.77% | |
| TRVI |
Trevi Therapeutics, Inc.
Healthcare
|
NEW | 2,166,504 | $25,846,392 | 0.72% | |
| LXEO |
Lexeo Therapeutics, Inc.
Healthcare
|
Held | 4,475,000 | $25,686,500 | 0.72% | |
| SLNO |
Soleno Therapeutics Inc
Healthcare
|
NEW | 730,000 | $24,440,400 | 0.68% | |
| BBNX |
Beta Bionics, Inc.
Healthcare
|
Added | 2,211,518 | $22,159,410 | 0.62% | |
| NKTR |
Nektar Therapeutics
Healthcare
|
NEW | 285,000 | $20,505,750 | 0.57% | |
| CYTK |
Cytokinetics Inc
Healthcare
|
NEW | 300,000 | $19,773,000 | 0.55% | |
| AZN |
Astrazeneca PLC
Healthcare
|
NEW | 100,000 | $19,722,000 | 0.55% |
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.